Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists.

摘要: Stereotactic ablative radiotherapy (SABR) is a novel radiation treatment method that delivers an intense dose of to the targets with high accuracy. The excellent local control and tolerance profile SABR have made it become important modality in cancer treatment. radiobiology key factor understanding further optimizing benefits SABR. In this review, we addressed several issues from perspective clinical oncologists. appropriateness linear-quadratic (LQ) model for controversial based on preclinical data, but reliable tool application because biological effective (BED) calculated can represent tumor probability (TCP). Hypoxia common phenomenon spite relatively small size has negative effect efficacy Preliminary studies indicate hypoxic radiosensitizer combined may be feasible strategy, so far there not adequate evidence support its routine practice. vascular change endothelial apoptosis blood perfusion reduction enhance response cells radiation. Combination anti-angiogenesis therapy shown promising good advanced cancers. more powerful enhancing antitumor immunity works better immune checkpoint inhibitors (ICIs) than conventional fractionation radiotherapy. ICIs practical option patients metastases.